Heraklion – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 01 Sep 2026 04:48:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Heraklion – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis https://clinicaltrials.eu/trial/a-study-testing-xmab942-compared-to-placebo-in-adults-with-moderate-to-severe-active-ulcerative-colitis/ Fri, 28 Aug 2026 11:41:56 +0000 https://clinicaltrials.eu/trial/a-study-testing-xmab942-compared-to-placebo-in-adults-with-moderate-to-severe-active-ulcerative-colitis/ This study involves Ulcerative Colitis, which is a long-lasting condition affecting the bowel where the lining of the large intestine and rectum becomes inflamed. The inflammation can cause symptoms that come and go over time. The treatment being tested is called XmAb942, which is an experimental medication given through infusion. Some participants will receive XmAb942 while others will receive placebo.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

]]> Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study https://clinicaltrials.eu/trial/efficacy-and-safety-of-oral-pipe-791-in-adults-with-idiopathic-pulmonary-fibrosis-a-phase-2-randomized-double-blind-placebo-controlled-study/ Fri, 28 Aug 2026 04:34:56 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-oral-pipe-791-in-adults-with-idiopathic-pulmonary-fibrosis-a-phase-2-randomized-double-blind-placebo-controlled-study/ Idiopathic Pulmonary Fibrosis is a rare lung condition in which scar tissue slowly builds up in the lungs, making it harder to breathe over time. The study is testing an oral tablet called PIPE-791 and comparing it with a placebo to see if the medicine can slow the loss of lung function.

The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

]]> Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease https://clinicaltrials.eu/trial/safety-of-pf-07872412-versus-20-valent-pneumococcal-conjugate-vaccine-in-healthy-infants-for-prevention-of-pneumococcal-disease/ Thu, 20 Aug 2026 04:04:01 +0000 https://clinicaltrials.eu/trial/safety-of-pf-07872412-versus-20-valent-pneumococcal-conjugate-vaccine-in-healthy-infants-for-prevention-of-pneumococcal-disease/ The study involves healthy infants and a vaccine that aims to protect against pneumococcal disease, an infection that can cause ear infections, pneumonia, and meningitis. The new product being tested is called the PG4 vaccine and it is compared with an already approved vaccine, Prevenar 20. Both vaccines are given by an intramuscular injection, which means the medicine is delivered into a muscle.

The purpose of the study is to describe the safety profile of the PG4 vaccine. Infants receive a single dose of either the study vaccine or the comparison vaccine and are then observed for a short time after the injection, followed by scheduled visits to check their health over the next weeks.

Researchers will watch for common side effects such as redness, swelling, pain at the injection site, fever, reduced appetite, irritability, or increased sleep. Any side effects, known as adverse events, and any serious side effects that require medical attention, called serious adverse events, will be recorded and reviewed.

]]> Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence https://clinicaltrials.eu/trial/study-comparing-imlunestrant-with-standard-endocrine-therapy-for-patients-with-early-er-her2-breast-cancer-at-increased-risk-of-recurrence/ Wed, 19 Aug 2026 04:02:58 +0000 https://clinicaltrials.eu/trial/study-comparing-imlunestrant-with-standard-endocrine-therapy-for-patients-with-early-er-her2-breast-cancer-at-increased-risk-of-recurrence/ This clinical trial is focused on studying treatments for early-stage breast cancer, specifically for patients who have a type of breast cancer known as ER-positive and HER2-negative. These terms refer to the presence of certain receptors on cancer cells that can influence how the cancer grows and responds to treatment. The study is comparing a new treatment called imlunestrant with standard treatments that are commonly used to block the effects of estrogen, a hormone that can promote the growth of some breast cancers. The standard treatments being compared include medications like tamoxifen, exemestane, anastrozole, letrozole, and gonadotropin-releasing hormone analogues.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

]]> Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese https://clinicaltrials.eu/trial/study-of-mirikizumab-and-tirzepatide-for-adults-with-moderate-to-severe-crohns-disease-who-are-overweight-or-obese/ Fri, 14 Aug 2026 04:03:45 +0000 https://clinicaltrials.eu/trial/study-of-mirikizumab-and-tirzepatide-for-adults-with-moderate-to-severe-crohns-disease-who-are-overweight-or-obese/ This study focuses on people who have both Crohn’s Disease (a long-term condition causing inflammation in the digestive system) and are either overweight or have obesity. The study will test two medications: mirikizumab (an injectable medication that helps reduce inflammation) and tirzepatide (an injectable medication that may help with weight management). The purpose is to see if using both medications together works better than using mirikizumab alone for improving both Crohn’s Disease symptoms and helping with weight loss.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

]]> Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis https://clinicaltrials.eu/trial/phase-iib-study-of-azd8965-versus-placebo-in-adults-with-idiopathic-pulmonary-fibrosis/ Sat, 08 Aug 2026 04:43:20 +0000 https://clinicaltrials.eu/trial/phase-iib-study-of-azd8965-versus-placebo-in-adults-with-idiopathic-pulmonary-fibrosis/ The study focuses on people with Idiopathic Pulmonary Fibrosis, a rare condition in which scar tissue forms in the lungs and makes breathing progressively harder. The investigational medication being examined is AZD8965, an oral tablet taken by mouth, while another group will receive a placebo that looks the same but does not contain the active drug.

The purpose of the trial is to determine whether AZD8965 can reduce the loss of lung function compared with placebo, using the change in FVC (forced vital capacity, the amount of air exhaled forcefully after a deep breath) as the main measure over about 24 weeks. Participants will be screened, then randomly assigned to receive either the study drug or placebo for a six‑month period, with regular clinic visits for safety checks, blood samples, and simple breathing tests. Throughout the study, any side effects and overall health will be closely monitored.

]]> Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease https://clinicaltrials.eu/trial/study-of-jnj-78934804-guselkumab-and-golimumab-versus-guselkumab-in-adults-with-moderately-to-severely-active-crohn-s-disease/ Sat, 08 Aug 2026 04:43:19 +0000 https://clinicaltrials.eu/trial/study-of-jnj-78934804-guselkumab-and-golimumab-versus-guselkumab-in-adults-with-moderately-to-severely-active-crohn-s-disease/ Crohn’s Disease is a long‑lasting condition that causes inflammation in the digestive tract, leading to abdominal pain, diarrhea, weight loss and fatigue. The study focuses on people whose disease is moderately to severely active, meaning symptoms are frequent and affect daily life. The investigational medicine being tested is called JNJ-78934804, which contains two active substances, guselkumab and golimumab. It is given as a liquid that is injected subcutaneous (under the skin) using a pre‑filled syringe. For comparison, another group receives only guselkumab in the same type of injection.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

]]> Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis https://clinicaltrials.eu/trial/efficacy-and-safety-of-jnj-78934804-guselkumab-and-golimumab-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ Sat, 08 Aug 2026 04:43:19 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-jnj-78934804-guselkumab-and-golimumab-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ The study focuses on ulcerative colitis, a condition where the lining of the large intestine becomes inflamed, causing diarrhea, abdominal pain, and bleeding. The trial includes people whose disease is moderate to severe, meaning symptoms are frequent and affect daily life. The investigational medicine is identified as JNJ-78934804, which contains two active substances, guselkumab and golimumab, and is given as a subcutaneous injection (a shot under the skin). For comparison, participants may receive the approved drug guselkumab alone, also given as a subcutaneous injection.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

]]> A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effect-of-muvalaplin-on-reducing-major-cardiovascular-events-in-adults-with-high-levels-of-lipoprotein-a-and-atherosclerotic-cardiovascular-disease/ Sat, 08 Aug 2026 04:43:08 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effect-of-muvalaplin-on-reducing-major-cardiovascular-events-in-adults-with-high-levels-of-lipoprotein-a-and-atherosclerotic-cardiovascular-disease/ This study focuses on individuals with high levels of Lipoprotein(a), which is a type of fatty particle in the blood that can increase the risk of heart issues. The research also involves people living with Atherosclerotic Cardiovascular Disease, a condition where plaque builds up in the arteries, potentially leading to serious health problems. The purpose of this study is to evaluate whether the drug muvalaplin can help reduce the occurrence of Major Adverse Cardiovascular Events, which are serious heart-related problems such as heart attacks or strokes.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

]]> Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-treprostinil-palmitil-inhalation-powder-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease/ Mon, 03 Aug 2026 10:45:46 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-treprostinil-palmitil-inhalation-powder-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease/ The study focuses on Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD), a condition in which high blood pressure in the lungs occurs together with scarring of lung tissue, leading to shortness of breath and reduced ability to exercise. The treatment being examined is an inhaled medication called Treprostinil Palmitil Inhalation Powder, also referred to by the code name TPIP, which is taken as a dry‑powder capsule that is breathed in.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

]]> A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease https://clinicaltrials.eu/trial/a-phase-3-study-of-enpatoran-to-treat-active-cutaneous-lupus-in-patients-with-or-without-systemic-disease/ Mon, 03 Aug 2026 10:45:44 +0000 https://clinicaltrials.eu/trial/a-phase-3-study-of-enpatoran-to-treat-active-cutaneous-lupus-in-patients-with-or-without-systemic-disease/ The study focuses on people who have Cutaneous Manifestations of Lupus Erythematosus, a form of lupus that causes red patches, rashes, and sometimes scarring on the skin, with or without involvement of other organs. Lupus is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues. The medication being tested is an oral tablet called Enpatoran. Participants will receive either this tablet or a matching placebo while continuing any standard treatments they already use.

The main purpose of the study is to determine whether Enpatoran can lower skin disease activity. Participants will take the study medication daily for about 24 weeks and will attend regular clinic visits to check their skin and overall health. Skin severity will be measured with a tool called the CLASI, which gives a number based on how much of the skin is affected and how severe the rash is. Overall lupus activity may also be evaluated using the BICLA score. Safety will be monitored by recording any side effects, referred to as TEAEs. The study will finish after the 24‑week period, and the results will show whether the drug provided a meaningful improvement.

]]> Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis https://clinicaltrials.eu/trial/study-of-ly4268989-adipic-acid-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ Mon, 03 Aug 2026 10:45:43 +0000 https://clinicaltrials.eu/trial/study-of-ly4268989-adipic-acid-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ The study focuses on adults who have Ulcerative Colitis that is moderately to severely active, meaning the colon is inflamed and causes frequent diarrhea, abdominal pain, and blood in the stool. The investigational medicine being tested is identified by the code name LY4268989, which is taken as an oral tablet. For comparison, participants may receive a matching placebo, which looks the same but does not contain the active drug.

The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

]]> Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis https://clinicaltrials.eu/trial/phase-2-study-of-nemolizumab-in-adult-patients-with-systemic-sclerosis-to-assess-skin-thickness-and-safety/ Mon, 03 Aug 2026 10:45:33 +0000 https://clinicaltrials.eu/trial/phase-2-study-of-nemolizumab-in-adult-patients-with-systemic-sclerosis-to-assess-skin-thickness-and-safety/ Systemic sclerosis is a rare condition that causes the skin to become thick and hard and can affect internal organs such as the lungs and heart. The study is testing an investigational drug called nemolizumab, which is given as a small injection under the skin, compared with a matching placebo. The medication is being examined to see if it can improve the skin changes and be safe for long‑term use.

The purpose of the study is to determine whether the drug can reduce skin thickness and be tolerated well over an extended period.

Participants will receive either the study medication or placebo by injection regularly for about one year and may continue for up to three years if they choose to stay in the extension phase. During the study, doctors will check the skin using a tool called the modified Rodnan Skin Score, which rates how tight the skin feels, and will perform a breathing test known as forced vital capacity to monitor lung function. Routine check‑ups will also include simple safety measurements such as blood tests, vital signs, and questions about any side effects.

]]> Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-admilparant-in-adults-with-idiopathic-or-progressive-pulmonary-fibrosis/ Mon, 03 Aug 2026 10:45:33 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-admilparant-in-adults-with-idiopathic-or-progressive-pulmonary-fibrosis/ The study focuses on two lung conditions, Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis, in which scar tissue builds up in the lungs and makes breathing harder. The treatment being examined is an oral tablet called Admilparant, which belongs to a group of medicines that aim to reduce the formation of scar tissue. The tablet is taken by mouth and is designed for long‑term use.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

]]> Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-of-spy001-001-spy002-and-spy003-alone-or-in-combination-in-patients-with-ulcerative-colitis/ Mon, 03 Aug 2026 10:45:32 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-of-spy001-001-spy002-and-spy003-alone-or-in-combination-in-patients-with-ulcerative-colitis/ Ulcerative colitis is a form of Inflammatory Bowel Disease that causes long‑lasting inflammation of the large intestine, leading to symptoms such as abdominal pain, diarrhea, and bleeding. The trial will evaluate several experimental long‑acting antibodies—identified by the code names SPY001-001, SPY003, and SPY002—which are given as a solution for injection under the skin. A matching inactive substance, called SPYPBO-101, will be used as a control.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.

]]> Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer https://clinicaltrials.eu/trial/randomized-phase-3-study-of-zl-1310-versus-topotecan-hydrochloride-in-patients-with-relapsed-small-cell-lung-cancer/ Mon, 03 Aug 2026 10:45:21 +0000 https://clinicaltrials.eu/trial/randomized-phase-3-study-of-zl-1310-versus-topotecan-hydrochloride-in-patients-with-relapsed-small-cell-lung-cancer/ The study focuses on adults with Small Cell Lung Cancer that has returned after previous therapy. One group will receive an experimental medicine called ZL-1310, which is designed to target a protein called DLL3 on cancer cells and deliver a cell‑killing payload. The other group will receive a standard chemotherapy drug known as topotecan hydrochloride, which can be taken as a pill or given through a vein (intravenous). “Relapsed” means the cancer has come back, and “antibody drug conjugate” refers to a lab‑made antibody that carries a drug directly to cancer cells.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

]]> Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-of-remibrutinib-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Mon, 03 Aug 2026 10:45:00 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-of-remibrutinib-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study is being done in adults with hidradenitis suppurativa, a long-lasting skin disease that can cause painful lumps, swelling, and drainage under the skin. The study uses remibrutinib, also known by the code name LOU064, taken as a tablet by mouth. Some participants will receive different doses of remibrutinib, and some will receive placebo. The purpose of the study is to assess the long-term safety of remibrutinib in this condition.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

]]> BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases https://clinicaltrials.eu/trial/bi-764198-in-adults-and-adolescents-with-proteinuric-kidney-diseases/ Mon, 03 Aug 2026 10:44:58 +0000 https://clinicaltrials.eu/trial/bi-764198-in-adults-and-adolescents-with-proteinuric-kidney-diseases/ This clinical trial is studying proteinuric kidney diseases, which are kidney disorders that cause too much protein to leak into the urine. The study is testing BI 764198, an oral tablet, against a placebo matching BI 764198. The purpose of the study is to see whether BI 764198 is safe and helpful for adults and adolescents with four related kidney conditions: focal segmental glomerulosclerosis (a kidney disease that scars parts of the kidney filter), treatment-resistant primary minimal change disease (a kidney disease that does not improve with usual treatment), Alport syndrome (an inherited kidney disease that can also affect hearing and vision), and treatment-resistant primary membranous nephropathy (a kidney disease caused by damage to the kidney filters). Some participants may already be receiving other kidney medicines such as SGLT2i/CNI, which are drugs often used to protect kidney function and reduce protein loss in the urine.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

]]> Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/nipocalimab-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ Mon, 03 Aug 2026 10:44:54 +0000 https://clinicaltrials.eu/trial/nipocalimab-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ This study is being done in adults with Systemic Lupus Erythematosus, a long-term disease in which the immune system attacks the body’s own tissues. The treatment being tested is nipocalimab, given as an injection under the skin, compared with placebo. The purpose of the study is to see whether nipocalimab can reduce disease activity in people with this condition.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

]]> GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents https://clinicaltrials.eu/trial/gb-0895-as-add-on-treatment-for-adults-and-adolescents-with-severe-uncontrolled-asthma/ Mon, 03 Aug 2026 10:44:46 +0000 https://clinicaltrials.eu/trial/gb-0895-as-add-on-treatment-for-adults-and-adolescents-with-severe-uncontrolled-asthma/ This clinical trial is studying severe uncontrolled asthma, a form of asthma in which breathing problems and flare-ups are not well controlled with usual treatment. The study is testing GB-0895, given as a subcutaneous injection under the skin, as an extra treatment along with regular asthma care. A placebo is also used for comparison. The purpose of the study is to see whether GB-0895 can help reduce serious asthma flare-ups and whether it is safe to use over time.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

]]> Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy https://clinicaltrials.eu/trial/study-of-human-normal-immunoglobulin-to-prevent-major-infections-in-patients-with-hypogammaglobulinemia-and-autoimmune-rheumatic-disease-on-b-cell-depletion-therapy/ Mon, 03 Aug 2026 10:44:44 +0000 https://clinicaltrials.eu/trial/study-of-human-normal-immunoglobulin-to-prevent-major-infections-in-patients-with-hypogammaglobulinemia-and-autoimmune-rheumatic-disease-on-b-cell-depletion-therapy/ The trial looks at people who have low levels of antibodies (called hypogammaglobulinemia) and who also have conditions where the immune system attacks the body, such as autoimmune or rheumatic conditions. These patients often receive medicines that remove B cells (B-cell depletion therapy), which can further weaken the immune system and increase the risk of serious infections. The study tests an intravenous solution of Panzyga, which contains human normal immunoglobulin, compared with a simple salt solution (sodium chloride) used as a placebo.

The aim is to see if adding Panzyga can lower the chance of a major infection or death in this vulnerable group. Participants will receive the assigned infusion once every few weeks for several months, and they will be checked regularly by doctors for any signs of infection, side effects, or changes in health. The study is set up so that neither the participants nor the doctors know which infusion is being given, to keep the comparison fair.

Throughout the trial, any infection that occurs will be recorded, and an independent group of experts will decide whether it meets the definition of a major infection. Safety will also be monitored by looking at reported side effects and routine lab tests. The information gathered will help determine whether the treatment is safe and effective for preventing serious infections in people with weak immune systems due to their underlying disease and therapy.

]]> Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-blinatumomab-and-a-drug-combination-for-older-adults-with-newly-diagnosed-philadelphia-negative-b-cell-precursor-acute-lymphoblastic-leukemia/ Mon, 03 Aug 2026 10:43:54 +0000 https://clinicaltrials.eu/trial/study-of-blinatumomab-and-a-drug-combination-for-older-adults-with-newly-diagnosed-philadelphia-negative-b-cell-precursor-acute-lymphoblastic-leukemia/ This study focuses on older adults with a newly diagnosed type of cancer called B-cell precursor Acute Lymphoblastic Leukemia. Specifically, the study looks at patients who are Philadelphia-negative, which means their cancer cells do not have a specific genetic marker. The purpose of the study is to compare a new treatment approach to the current standard of care to see how well it works and how safe it is.

Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.

The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.

]]> A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer https://clinicaltrials.eu/trial/a-study-of-pf-08634404-and-a-drug-combination-in-adults-with-advanced-or-metastatic-non-small-cell-lung-cancer/ Mon, 03 Aug 2026 10:43:46 +0000 https://clinicaltrials.eu/trial/a-study-of-pf-08634404-and-a-drug-combination-in-adults-with-advanced-or-metastatic-non-small-cell-lung-cancer/ This study is designed to compare the effectiveness and safety of two different treatment approaches for adults with Non-Small Cell Lung Cancer that is either Locally Advanced or Metastatic. This means the cancer is either growing into nearby tissues or has spread to other parts of the body. The purpose of the study is to determine if a new medicine, PF-08634404, used along with Chemotherapy, works better than a current treatment combining Pembrolizumab with chemotherapy.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

]]> A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-vixarelimab-in-patients-with-moderate-to-severe-ulcerative-colitis/ Mon, 03 Aug 2026 10:43:41 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-vixarelimab-in-patients-with-moderate-to-severe-ulcerative-colitis/ This study focuses on individuals living with Ulcerative Colitis, a long-term condition that causes inflammation and sores in the lining of the large intestine. The purpose of the study is to evaluate the efficacy of vixarelimab compared to a placebo in achieving clinical remission, which is a state where symptoms of the disease are significantly reduced or gone. Participants in the study may also be taking other medications as part of their usual care, such as azathioprine, adalimumab, methotrexate, golimumab, infliximab, mercaptopurine, corticosteroids, or aminosalicylates.

The study consists of an initial phase to see how well the treatment works to control symptoms, followed by an extension period to continue monitoring the effects. During the study, medical professionals will monitor the levels of vixarelimab in the blood and check for anti-drug antibodies, which are substances the body might create in response to a medication. The course of the study involves regular assessments to observe changes in symptoms and the condition of the intestinal lining.

]]> A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS) https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effects-of-bi-764198-in-adults-and-adolescents-with-focal-segmental-glomerulosclerosis-fsgs/ Mon, 03 Aug 2026 10:43:38 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effects-of-bi-764198-in-adults-and-adolescents-with-focal-segmental-glomerulosclerosis-fsgs/ This study investigates the effects of a medication called BI 764198 in people with Focal Segmental Glomerulosclerosis, which is a rare kidney disease that damages the small filtering units in the kidneys. The study specifically looks at individuals with primary focal segmental glomerulosclerosis or those with a version of the disease caused by TRPC6 gene mutations, which are changes in the genetic code that affect how the disease behaves. Some participants may also be taking a calcineurin inhibitor, which is a type of medicine used to manage certain immune-related conditions.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

]]> A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-tenecteplase-in-patients-with-acute-ischemic-stroke-who-are-more-than-4-5-hours-after-their-last-known-well-time/ Mon, 03 Aug 2026 10:43:34 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-tenecteplase-in-patients-with-acute-ischemic-stroke-who-are-more-than-4-5-hours-after-their-last-known-well-time/ This study focuses on Acute Ischemic Stroke, a condition that occurs when a blood vessel supplying the brain becomes blocked, preventing oxygen from reaching brain cells. The research aims to evaluate the effectiveness and safety of tenecteplase compared to the current standard medical treatments. This study is specifically looking at individuals who were last seen well more than 4.5 hours before receiving treatment, including cases known as wake-up stroke, where the exact time the symptoms started is unknown. This group includes people who show evidence through imaging, such as a computed tomography scan, that there is still salvageable brain tissue that can be saved if blood flow is restored.

During the trial, participants will receive either tenecteplase or the standard of care via an intravenous bolus, which is a method of delivering medication directly into a vein in a single quick dose. The study will monitor how well patients recover and function over a period of time, specifically looking at their ability to perform daily activities 90 days after the event. The researchers will also observe for any potential side effects, such as symptomatic intracranial hemorrhage, which is a type of bleeding inside the brain that can occur following treatment.

]]> A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-ritlecitinib-tosilate-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Mon, 03 Aug 2026 10:43:34 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-ritlecitinib-tosilate-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This study focuses on individuals living with Hidradenitis Suppurativa, a chronic skin condition characterized by painful, red lumps under the skin that can form abscesses or tunnels. The purpose of the study is to evaluate the safety and effectiveness of a medication called ritlecitinib, also known as PF-06651600, compared to a placebo.

During the study, participants will be assigned to receive either the active medication or a placebo in a randomized way, meaning the group assignment is decided by chance. The process is double-blind, which means neither the participants nor the researchers know which substance is being administered. The study will last for a total of 16 weeks, during which time the effects of the treatment on the skin and symptoms will be monitored.

]]> A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis https://clinicaltrials.eu/trial/a-study-of-the-humanised-igg1-lalaps-yte-monoclonal-antibody-against-lysophosphatidic-acid-receptor-1-to-treat-adults-with-idiopathic-pulmonary-fibrosis/ Mon, 03 Aug 2026 10:43:31 +0000 https://clinicaltrials.eu/trial/a-study-of-the-humanised-igg1-lalaps-yte-monoclonal-antibody-against-lysophosphatidic-acid-receptor-1-to-treat-adults-with-idiopathic-pulmonary-fibrosis/ This study focuses on individuals with Idiopathic Pulmonary Fibrosis, a condition where the lungs become scarred and thickened over time, making it harder to breathe. The goal of the study is to evaluate the safety and effectiveness of a new investigational medicine called ABBV-142. This treatment is a humanised igg1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1, which is a type of protein-based medicine designed to target specific processes in the body. ABBV-142 will be given to participants through intravenous administration, meaning it is delivered directly into a vein as a solution for injection/infusion.

During the study, some participants will receive the active medicine, while others will receive a placebo. The research involves monitoring how the medicine affects the body over a period of time to see if it can change the way the disease progresses. The course of the study includes regular check-ups to observe any changes in health or how the lungs are functioning.

]]> A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a) https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effect-of-olpasiran-on-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease-and-high-levels-of-lipoprotein-a/ Mon, 03 Aug 2026 10:43:26 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effect-of-olpasiran-on-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease-and-high-levels-of-lipoprotein-a/ This study investigates the effects of olpasiran in individuals diagnosed with atherosclerotic cardiovascular disease, a condition where plaque builds up in the arteries, and elevated lipoprotein (a), which is a specific type of fatty protein found in the blood. The purpose of the study is to compare the impact of the study drug against a placebo on the risk of major heart-related issues. These issues include coronary heart disease death, myocardial infarction, or the need for urgent coronary revascularization, which is a procedure used to restore blood flow to the heart.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

]]> A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn’s disease or ulcerative colitis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-and-effectiveness-of-balinatunfib-in-adults-with-crohn-s-disease-or-ulcerative-colitis/ Mon, 03 Aug 2026 10:43:25 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-and-effectiveness-of-balinatunfib-in-adults-with-crohn-s-disease-or-ulcerative-colitis/ This study aims to investigate the long-term safety and effectiveness of balinatunfib in adults living with Crohn’s disease or ulcerative colitis. These are types of inflammatory bowel disease, which is a condition that causes long-lasting swelling and irritation in the digestive tract. Participants in the study will receive either balinatunfib, which is an oral medication taken by mouth in the form of a film-coated tablet, or a placebo.

The research focuses on how different doses of the medication affect people over an extended period. During the course of the study, the way the body reacts to the treatment and any potential side effects will be monitored to ensure safety and how well the body tolerates the drug.

]]> A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-nucresiran-and-vutrisiran-in-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy/ Mon, 03 Aug 2026 10:43:12 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-nucresiran-and-vutrisiran-in-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy/ This study focuses on a rare condition called Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. In this disease, an abnormal protein builds up in the body, which can cause damage to the nerves, leading to issues with movement and sensation. The purpose of the study is to evaluate the effectiveness and safety of a new medication called nucresiran.

Participants in the study will receive either nucresiran or vutrisiran, which is a currently used treatment for this condition. These medications are administered as a subcutaneous injection, meaning the medicine is injected into the fatty tissue just under the skin. During the study, the effects of these drugs on nerve function and the levels of a protein called transthyretin in the blood will be observed over time.

]]> A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-and-effectiveness-of-sonelokimab-in-patients-with-psoriatic-arthritis/ Mon, 03 Aug 2026 10:43:11 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-and-effectiveness-of-sonelokimab-in-patients-with-psoriatic-arthritis/ This study focuses on individuals living with psoriatic arthritis, a type of inflammatory arthritis that often affects both the skin and the joints. The purpose of this study is to evaluate the long-term safety and effectiveness of a medication called sonelokimab. This treatment is administered through a subcutaneous injection, which is a method of delivering medication into the fatty layer of tissue just beneath the skin.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

]]> A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-azd5148-in-preventing-the-recurrence-of-clostridioides-difficile-infection-in-adults/ Mon, 03 Aug 2026 10:43:09 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-azd5148-in-preventing-the-recurrence-of-clostridioides-difficile-infection-in-adults/ This study investigates a way to prevent the return of Clostridioides difficile infection, a type of infection in the gut that often causes severe diarrhea. The research aims to determine if a new medication can reduce how often the infection comes back after the initial treatment. The medication being tested is called AZD5148, which is a monoclonal antibody. A monoclonal antibody is a type of protein made in a laboratory that is designed to find and attach to specific targets in the body, such as the toxin B produced by the bacteria.

Participants in the study will receive either AZD5148 or a placebo. The medication will be given as an intravenous infusion, which means it is delivered directly into a vein through a needle or tube. This treatment is administered alongside standard care, which includes regular antibacterial drugs used to treat the current infection. During the study, individuals will be monitored to see if the infection returns within a specific period of time.

]]> A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn’s disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-duvakitug-in-patients-with-moderate-to-severe-crohn-s-disease/ Mon, 03 Aug 2026 10:43:08 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-duvakitug-in-patients-with-moderate-to-severe-crohn-s-disease/ This study is being conducted to evaluate the efficacy and safety of duvakitug in individuals with Crohn’s disease. Crohn’s disease is a type of immune system disease that causes inflammation in the digestive tract. The investigation focuses on how well duvakitug works as a maintenance therapy, which is a treatment used to keep symptoms under control and prevent flares of the disease over a long period.

Participants in the study will receive either duvakitug or a placebo through a subcutaneous injection, which is a shot administered just under the skin. This is a randomized study, meaning participants are assigned to a group by chance, and it is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The study involves monitoring the condition over a period of time to observe how the body responds to the medication.

]]> A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-admilparant-in-patients-with-progressive-pulmonary-fibrosis/ Mon, 03 Aug 2026 10:43:04 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-admilparant-in-patients-with-progressive-pulmonary-fibrosis/ This study aims to evaluate the efficacy and safety of a study drug known as BMS-986278, also referred to as admilparant, in individuals living with Progressive Pulmonary Fibrosis. Progressive Pulmonary Fibrosis is a condition where the lung tissue becomes thick and scarred over time, making it harder to breathe. The treatment being tested is an LPA1 antagonist, which is a type of medication designed to block specific signals in the body that may contribute to the scarring of the lungs. This medication is taken as an oral use film-coated tablet.

Participants in the study will be randomly assigned to receive either the active medication or a placebo. The study is double-blind, meaning that neither the participants nor the researchers will know which specific treatment is being administered during the course of the trial. The process involves monitoring changes in Forced Vital Capacity, which is a measurement of the total amount of air a person can exhale from their lungs after taking a deep breath. The study will track these changes and other health factors over a period of time to see how the medication affects the progression of the disease.

]]> Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/efficacy-and-safety-of-subcutaneous-belimumab-in-adults-with-connective-tissue-disease-associated-interstitial-lung-disease/ Mon, 03 Aug 2026 10:42:50 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-subcutaneous-belimumab-in-adults-with-connective-tissue-disease-associated-interstitial-lung-disease/ This clinical trial is focused on studying a group of lung conditions known as Interstitial Lung Disease (ILD), which are associated with Connective Tissue Disease (CTD). These diseases can cause scarring of the lungs, leading to breathing difficulties. The study will evaluate the effectiveness and safety of a medication called Belimumab, which is given as an injection under the skin. Belimumab is being tested to see if it can help reduce the decline in lung function in people with ILD related to CTD.

The trial will compare the effects of Belimumab to a placebo, in addition to the standard treatments that participants are already receiving for their condition. Participants will receive either Belimumab or a placebo through injections over a period of 52 weeks. The main goal is to see if Belimumab can help maintain lung volume better than the placebo. Throughout the study, participants will be monitored for changes in their lung function and overall health.

Participants in the study will be adults who have been diagnosed with ILD associated with CTD, such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), or other similar conditions. The study aims to provide more information on whether Belimumab can be a beneficial addition to the current treatment options for these lung diseases. The trial will also track any side effects or health changes experienced by participants during the study period.

]]> A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy https://clinicaltrials.eu/trial/a-study-of-mevrometostat-and-enzalutamide-for-men-with-metastatic-castration-sensitive-prostate-cancer-who-have-not-received-hormonal-therapy-or-chemotherapy/ Mon, 03 Aug 2026 10:42:39 +0000 https://clinicaltrials.eu/trial/a-study-of-mevrometostat-and-enzalutamide-for-men-with-metastatic-castration-sensitive-prostate-cancer-who-have-not-received-hormonal-therapy-or-chemotherapy/ This study involves men with metastatic castration-sensitive prostate cancer, which is a type of prostate cancer that has spread to other parts of the body but still responds to treatments that lower testosterone levels. The study will test a combination of two medications: mevrometostat, which is also known by its code name PF-06821497, and enzalutamide, which is already used to treat prostate cancer. Some participants will receive mevrometostat together with enzalutamide, while others will receive placebo together with enzalutamide. The purpose of the study is to find out if adding mevrometostat to enzalutamide can help delay the worsening of the cancer compared to using enzalutamide with placebo.

During the study, participants will take their assigned medications by mouth as tablets or capsules. They will continue their ongoing hormone therapy that lowers testosterone levels throughout the study. The study will track how long it takes for the cancer to get worse by using imaging scans, which are special pictures of the inside of the body taken with machines. The study team will also monitor various aspects of health, including blood tests to measure a substance called prostate-specific antigen, pain levels, quality of life, and any side effects that may occur. Participants will attend regular visits where doctors will perform examinations and tests to assess how the treatment is working and how participants are feeling.

The study will also look at other important measures such as how long participants live, whether tumors shrink in response to treatment, how long any tumor shrinkage lasts, and how long it takes before additional cancer treatments are needed. Doctors will carefully monitor for any unwanted effects of the medications and will check participants’ overall well-being through questionnaires about pain, tiredness, and daily functioning. Blood samples will be taken at certain times to measure the levels of mevrometostat in the body and to examine genetic material from cancer cells that may be circulating in the blood.

]]> Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration https://clinicaltrials.eu/trial/study-of-surabgene-lomparvovec-compared-to-ranibizumab-for-adults-with-wet-age-related-macular-degeneration/ Mon, 03 Aug 2026 10:42:24 +0000 https://clinicaltrials.eu/trial/study-of-surabgene-lomparvovec-compared-to-ranibizumab-for-adults-with-wet-age-related-macular-degeneration/ This study involves people with neovascular age-related macular degeneration, a condition where abnormal blood vessels grow under the central part of the retina at the back of the eye, which can lead to vision loss. The study will test a treatment called surabgene lomparvovec, also known as ABBV-RGX-314, which is a gene therapy given as a single injection under the retina. This treatment is designed to help the eye produce its own medicine that blocks the growth of abnormal blood vessels. The study will compare this gene therapy to ranibizumab, which is an approved medicine given as repeated injections into the eye to treat this condition.

The purpose of this study is to find out how many injections people need after receiving the gene therapy compared to those who continue getting regular injections of ranibizumab, and to see how well the gene therapy works in preserving vision over time in a setting that is similar to everyday medical practice. The study will also look at the safety of the gene therapy and measure any side effects that may occur in the treated eye or the other eye. Additionally, the study will check for changes in areas of damage in the central part of the retina.

People taking part in the study will be randomly assigned to receive either the gene therapy or ranibizumab. Those who receive the gene therapy will have it injected under the retina during a surgical procedure, while those in the comparison group will receive ranibizumab injections into the eye as needed based on how their condition responds. During the first year, people will be monitored closely and receive additional injections if needed according to specific guidelines. After the first year, the treatment schedule will follow a more flexible approach that reflects how treatment is typically managed in regular clinics. The study will last for several years to see how well vision is maintained over the long term.

]]> Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor https://clinicaltrials.eu/trial/study-comparing-cagrilintide-and-semaglutide-versus-tirzepatide-in-people-with-type-2-diabetes-taking-metformin-or-sglt2-inhibitor/ Mon, 03 Aug 2026 10:42:22 +0000 https://clinicaltrials.eu/trial/study-comparing-cagrilintide-and-semaglutide-versus-tirzepatide-in-people-with-type-2-diabetes-taking-metformin-or-sglt2-inhibitor/ This study is looking at type 2 diabetes, a condition where the body does not properly control blood sugar levels. The study will test a combination medication called cagrilintide semaglutide, which contains two active substances that work together to help lower blood sugar and reduce body weight. This medication will be compared to another diabetes medicine called tirzepatide, which is available under the brand name Mounjaro. Both medications are given as injections under the skin once a week. The study will include people with type 2 diabetes who are already taking metformin, an SGLT2 inhibitor, or both of these medications, but whose blood sugar levels are not well controlled with these treatments alone.

The purpose of the study is to find out if cagrilintide semaglutide is at least as good as tirzepatide at lowering blood sugar levels, and whether it might be better at helping people lose weight. The study will also look at other health measures such as blood pressure, waist size, cholesterol levels, and overall quality of life. Additionally, the study will check how safe these medications are and what side effects people may experience while taking them.

People taking part in this study will receive either cagrilintide semaglutide or tirzepatide for 60 weeks. During this time, they will continue taking their current diabetes medications. Throughout the study, participants will have regular visits where their blood sugar levels, body weight, blood pressure, and other health measurements will be checked. Blood tests will be done to measure a substance called HbA1c, which shows average blood sugar levels over the past few months, as well as cholesterol and other blood fats. Participants will also be asked to complete questionnaires about their physical health and quality of life. The study team will monitor for any side effects, including episodes of low blood sugar, which can happen when blood sugar drops too much.

]]> Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment https://clinicaltrials.eu/trial/testing-mk-2870-with-pembrolizumab-compared-to-pembrolizumab-alone-after-surgery-in-patients-with-non-small-cell-lung-cancer-who-did-not-respond-fully-to-treatment/ Mon, 03 Aug 2026 10:42:21 +0000 https://clinicaltrials.eu/trial/testing-mk-2870-with-pembrolizumab-compared-to-pembrolizumab-alone-after-surgery-in-patients-with-non-small-cell-lung-cancer-who-did-not-respond-fully-to-treatment/ This clinical trial is studying non-small cell lung cancer that can be removed by surgery and is classified as Stage II, IIIA, or IIIB with lymph node involvement. The trial involves several treatment medications. The main treatments being tested are MK-2870, which is also known as sacituzumab tirumotecan, and pembrolizumab, which is marketed as Keytruda. Additional chemotherapy medications that may be used include paclitaxel, gemcitabine, pemetrexed, carboplatin, and cisplatin. Supportive medications such as paracetamol, codeine phosphate, antihistamines, and glucocorticoids may also be given to manage side effects. All of these medications are given through infusion into a vein or by other methods as needed.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

]]>